Overview

Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations

Status:
Not yet recruiting

Trial end date:
2023-12-30

Target enrollment:

Participant gender:

Summary

This is a phase III clinical trial aimed to compare the efficacy and safety of Osimertinib monotherapy and combination of Osimertinib, pemetrexed and carboplatin in untreated patients with advanced non-small cell lung cancer with concurrent EGFR and TP53 mutation.

Phase:

Phase 3

Details

Lead Sponsor:

Li Zhang, MD

Treatments:

Carboplatin
Osimertinib
Pemetrexed